HC Wainwright Predicts Stronger Earnings for Apyx Medical

Key Points

• HC Wainwright raised its FY2026 EPS forecast to a loss of $0.21 per share from $0.25, while maintaining a Buy rating and $7 price target. It forecasts a FY2027 loss of $0.22 per share.
• Apyx Medical reported a quarterly loss of $0.04 per share, beating analysts’ estimate of a $0.09 loss; revenue of $14.03 million also exceeded the $13.29 million consensus.
• Analyst sentiment is moderately positive: MarketBeat reports a consensus Moderate Buy rating and a $6.50 target price, with ratings ranging from Strong Buy to Sell.

Apyx Medical Corporation (NASDAQ:APYX - Free Report) - HC Wainwright upped their FY2026 earnings per share estimates for shares of Apyx Medical in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.21) for the year, up from their previous estimate of ($0.25). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Apyx Medical's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Apyx Medical's Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.

A number of other research analysts also recently commented on APYX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Apyx Medical in a research report on Monday, September 21st. Zacks Research upgraded shares of Apyx Medical to a "hold" rating in a research note on Tuesday, July 14th. Finally, Maxim Group initiated coverage on shares of Apyx Medical in a research report on Tuesday, September 29th. They issued a "buy" rating and a $6.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Apyx Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.

Apyx Medical Trading Up 0.3%

Shares of NASDAQ:APYX opened at $2.94 on Tuesday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68. Apyx Medical has a twelve month low of $2.25 and a twelve month high of $5.08. The firm has a 50 day simple moving average of $2.74 and a 200-day simple moving average of $3.58.

Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.05. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $13.29 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nwam LLC acquired a new stake in shares of Apyx Medical in the first quarter valued at approximately $47,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $62,000. AXQ Capital LP acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $78,000. Jefferies Financial Group Inc. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $110,000. Finally, Squarepoint Ops LLC purchased a new stake in Apyx Medical in the 2nd quarter valued at $144,000. Institutional investors and hedge funds own 55.33% of the company's stock.

More Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright increased its FY2026 EPS estimate to a loss of $0.21 from $0.25 and its FY2027 estimate to a loss of $0.22 from $0.25. It also raised quarterly forecasts, including Q4 2026 to a loss of $0.04 from $0.06 and Q1–Q3 2027 to losses of $0.06 each from $0.07. The firm reiterated its Buy rating and $7 target. MarketBeat APYX coverage
• Positive Sentiment: Maxim Group was reported to have maintained its Buy rating on APYX, offering additional analyst support, though this item is older than the latest estimate revisions. Maxim Group remains a Buy on Apyx Medical
• Neutral Sentiment: Apyx CEO Charles Goodwin presented at the 2026 UBS Global Healthcare Conference. The provided transcript listings do not identify a specific new announcement or outlook change. UBS conference transcript

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company's platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical's principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.